Silexion Therapeutics Corp Warrant (SLXNW) Financials

Silexion Therapeutics Corp Warrant (SLXNW) reported diluted earnings per share of $89.61 for fiscal year 2025. This represents a -97.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Silexion Therapeutics Corp Warrant (SLXNW) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Silexion Therapeutics Corp Warrant (SLXNW) has a return on equity of -457.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Silexion Therapeutics Corp Warrant (SLXNW) recorded an outflow of $10.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Silexion Therapeutics Corp Warrant (SLXNW) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Silexion Therapeutics Corp Warrant (SLXNW) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Silexion Therapeutics Corp Warrant (SLXNW) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Silexion Therapeutics Corp Warrant (SLXNW) invested $7.1M in research and development during fiscal year 2025.

Silexion Therapeutics Corp Warrant (SLXNW) had 3M shares outstanding as of fiscal year 2025.

Silexion Therapeutics Corp Warrant (SLXNW) had a current ratio of 2.41 as of fiscal year 2025, which is generally considered healthy.

Silexion Therapeutics Corp Warrant (SLXNW) had a liabilities-to-equity ratio of 1.77 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Silexion Therapeutics Corp Warrant (SLXNW) had a return on assets of -165.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, Silexion Therapeutics Corp Warrant (SLXNW) held $6.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Silexion Therapeutics Corp Warrant (SLXNW) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Silexion Therapeutics Corp Warrant (SLXNW) reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Silexion Therapeutics Corp Warrant (SLXNW) reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.